共 84 条
[1]
Amado RG(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634
[2]
Wolf M(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-2648
[3]
Peeters M(2009)Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663-671
[4]
Benvenuti S(2007)Panitumumab the first fully human monoclonal antibody: from the bench to the clinic Anticancer Drugs 18 7-15
[5]
Sartore-Bianchi A(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345
[6]
Di Nicolantonio F(2008)KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508-515
[7]
Bokemeyer C(2007)Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 1166-1169
[8]
Bondarenko I(2009)FDA narrows drug label usage Nature 460 1069-1047
[9]
Makhson A(2000)Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041-4705
[10]
Cohenuram M(2010)Randomized, phase 3 study (PRIME) of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer J Clin Oncol 28 4697-190